Refine
Document Type
- Doctoral Thesis (2)
Language
- English (2)
Has Fulltext
- yes (2)
Is part of the Bibliography
- no (2)
Keywords
- Vaccine (2) (remove)
Institute
- Abteilung für Mikrobiologie und Molekularbiologie (2) (remove)
The role of cell-penetrating peptides in the induction of T cell responses by virus-like particles
(2023)
Many viral structural proteins can self-assemble into virus-like particles (VLPs). VLPs can serve as an effective vaccine or be used as a vaccine platform. One of these structural proteins is the hepatitis B virus core antigen (HBcAg), which appears to be suitable as an antigen carrier due to its high immunogenicity. HBcAg has a major immunodominant region (MIR) that is presented on the surface of the VLPs after self-assembly. Foreign antigens can be inserted into this region. Since HBcAg VLPs, unlike the Hepatitis B virus (HBV), do not have an envelope, they are not able to penetrate cell membranes efficiently. As an extracellular antigen, HBcAg VLPs primarily induce a strong humoral immune response.
In the present study, we investigated the extent to which HBcAg can be modified to also elicit an enhanced cellular, particularly a cytotoxic, immune response. A cytotoxic CD8+ T cell response is predominantly induced by intracellular antigens. Therefore, our goal was to increase the cell penetration capacity of VLPs. We aimed to achieve this by fusing cell-penetrating peptides (CPPs) to HBcAg. CPPs can spontaneously penetrate cell membranes to enter the cytoplasm of cells. To guarantee that the CCPs were localized to the surface of the VLPs, we fused CPPs to the N-terminus of HBcAg. The CCPs were followed by a tag to allow the purification of VLPs. The T cell epitopes, against which the induced CTL should be directed, were derived from the Large T antigen and inserted into the MIR of HBcAg. Finally, we fused fluorescent proteins to the C-terminus of HBcAg to track the entry of VLPs into cells.
Modifications of HBcAg may lead to reduced stability or altered structure of VLPs. To analyze the stability of VLPs, we used nanoscale differential scanning fluorimetry (nanoDSF) analysis. This revealed that the N-terminal fusion of CPPs or the tag to HBcAg does not reduce VLP stability. However, some peptides incorporated into the MIR had a significant effect on the structure and stability of the VLPs. While the incorporation of a Flag-tag or a peptide from ovalbumin had no negative effect on VLP stability, the incorporation of peptides representing T cell epitopes of Large T antigen interfered with VLP formation. Denaturation and reassembly of the aggregates significantly improved the homogeneity of the VLPs, and the C-terminal addition of arginine-rich domains enhanced stability.
Using live cell imaging and flow cytometry, we demonstrated that HBcAg VLPs functionalized with CPP exhibited up to 40% more efficient penetration into professional antigen-presenting cells (JAWS II) than HBcAg VLPs without CPP. This resulted in the increased presentation of integrated T cell epitopes by dendritic cells. In vivo, we detected significantly increased induction of SV40 Large T antigen-specific CTL in mice immunized with CPP-conjugated VLPs compared to unconjugated VLPs.
In this study, we demonstrated that a stronger cellular immune response can be induced by CPP-functionalized HBcAg VLPs than with the unmodified HBcAg VLPs in vitro as well as in vivo. This discovery may have positive implications for future vaccine development where an enhanced cellular component of the immune response is desirable.
Gram-negative bacteria are known to naturally produce outer membrane vesicles (OMVs), which are closed nanoparticles (10 to 450 nm) containing virulence factors and pathogen associated molecular patterns (PAMPs). For over 20 years, OMVs of Neisseria meningitidis (N. meningitidis), in combination with three purified outer membrane proteins, have been successfully used as parts of human vaccines which illustrates the safety and potential of OMV based vaccines. So far only little is known about the OMVs of fish pathogenic bacteria. The production of OMVs has been described for the fish pathogenic gram-negative bacterium Aeromonas salmonicida (A. salmonicida) which is the causative agent of furunculosis resulting in high morbidity and mortality of salmonid fish. The immunostimulatory potential of OMVs derived from A. salmonicida as well as the possibility of establishing an oral vaccine model in Oncorhynchus mykiss (O.mykiss) (Rainbow trout) has been investigated in this study by conducting in vitro and in vivo experiments. Innate immune cells such as macrophages are one of the first cells to respond to pathogens once they breach the skin barrier, therefore the monocyte/macrophage cell line RTS-11 as well as leukocytes from the head kidney, consisting of a high percentage of phagocytic cells have been investigated. Additionally, leukocytes isolated from the peritoneal cavity as the main target for injectable vaccines have been studied in the in vitro experiments. These experiments indicate that OMVs derived from A. salmonicida are recognized by the monocyte/macrophage cell line RTS-11 as well as by leukocytes from the head kidney resulting in significant changes of the mRNA expression pattern of early inflammatory markers (IL-1β, IL-6, IL-8, IL-10, TGFβ). Having used the established peritoneal inflammation model of rainbow trout it could be shown that intraperitoneal (i.p.) vaccination of rainbow trout with OMVs results in a similar local immune response, especially in the recruitment of myeloid cells, compared to the injection of inactivated bacteria. The systemic cellular immune response differed between the two vaccine groups, even though a similar humoral immune response could be observed. Interestingly, i.p.vaccination with 10 µg of OMVs resulted in similar antibody titers as observed for fish, that were i.p. vaccinated with 108 CFU of inactivated A. salmonicida. The similar antibody titers after vaccination with OMVs might be explained by a stronger activation of CD8- T cells (likely CD4+ T cells) in the head kidney as well as in the blood in the OMV vaccinated group alone, which might result in an increased stimulation of B cells to produce antibodies.
Oral vaccination has been described as the ideal vaccination method for fish, but only few vaccines for oral application are licensed. Therefore, the established oral model for vaccination of rainbow trout with attenuated viral hemorrhagic septicemia virus (VHSV) was adapted to be used for inactivated A. salmonicida, even though initial trials indicated great similarities in the cellular response after i.p. and oral vaccination with inactivated strains of A. salmonicida, particularly in the response of the myeloid cells and lymphocytes in the target organs as well as the thrombocytes in the spleen. This could not be confirmed in a second oral vaccination trial. These results show how challenging the development of oral vaccines for fish is. The main challenge is the reproducibility of reliable results, since this is influenced by the difference in uptake of vaccine pellets or antigen degradation in the gut. Future oral vaccine trials should investigate different vaccination regimes, e.g., consecutive feeding, or a different composition of vaccine pellets, in order to further investigate the possibility of establishing an oral vaccine model for trout and so that future vaccine candidates, like OMVs, can be reliably tested in fish.